Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Subscribe To Our Newsletter & Stay Updated
